Inflammation as common link to progressive neurological diseases
- PMID: 37964100
- PMCID: PMC10761431
- DOI: 10.1007/s00204-023-03628-8
Inflammation as common link to progressive neurological diseases
Abstract
Life expectancy has increased immensely over the past decades, bringing new challenges to the health systems as advanced age increases the predisposition for many diseases. One of those is the burden of neurologic disorders. While many hypotheses have been placed to explain aging mechanisms, it has been widely accepted that the increasing pro-inflammatory status with advanced age or "inflammaging" is a main determinant of biological aging. Furthermore, inflammaging is at the cornerstone of many age-related diseases and its involvement in neurologic disorders is an exciting hypothesis. Indeed, aging and neurologic disorders development in the elderly seem to share some basic pathways that fundamentally converge on inflammation. Peripheral inflammation significantly influences brain function and contributes to the development of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Understanding the role of inflammation in the pathogenesis of progressive neurological diseases is of crucial importance for developing effective treatments and interventions that can slow down or prevent disease progression, therefore, decreasing its social and economic burden.
Keywords: Central nervous system; Cytokines; Immune response; Neurodegeneration; Neuroinflammation.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
CSF Cytokines in Aging, Multiple Sclerosis, and Dementia.Front Immunol. 2019 Mar 15;10:480. doi: 10.3389/fimmu.2019.00480. eCollection 2019. Front Immunol. 2019. PMID: 30930904 Free PMC article. Clinical Trial.
-
Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis.Free Radic Biol Med. 2018 Feb 1;115:80-91. doi: 10.1016/j.freeradbiomed.2017.10.379. Epub 2017 Nov 25. Free Radic Biol Med. 2018. PMID: 29080843 Review.
-
Co-signaling Molecules in Neurological Diseases.Adv Exp Med Biol. 2019;1189:233-265. doi: 10.1007/978-981-32-9717-3_9. Adv Exp Med Biol. 2019. PMID: 31758537 Review.
-
Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases.Int J Mol Sci. 2017 Dec 6;18(12):2633. doi: 10.3390/ijms18122633. Int J Mol Sci. 2017. PMID: 29211044 Free PMC article. Review.
-
The role of Th17 cells in auto-inflammatory neurological disorders.Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):408-416. doi: 10.1016/j.pnpbp.2017.07.023. Epub 2017 Jul 29. Prog Neuropsychopharmacol Biol Psychiatry. 2017. PMID: 28760387 Review.
Cited by
-
Global research trends in inflammaging from 2005 to 2024: a bibliometric analysis.Front Aging. 2025 Apr 10;6:1554186. doi: 10.3389/fragi.2025.1554186. eCollection 2025. Front Aging. 2025. PMID: 40276724 Free PMC article.
-
A transient blood IL-17 increase triggers neuroinflammation in cerebellum and motor incoordination in hyperammonemic rats.J Neuroinflammation. 2024 Nov 30;21(1):314. doi: 10.1186/s12974-024-03310-5. J Neuroinflammation. 2024. PMID: 39616376 Free PMC article.
-
Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies.Pharmaceuticals (Basel). 2025 Jan 15;18(1):104. doi: 10.3390/ph18010104. Pharmaceuticals (Basel). 2025. PMID: 39861166 Free PMC article. Review.
-
Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know?Brain Sci. 2023 Dec 23;14(1):19. doi: 10.3390/brainsci14010019. Brain Sci. 2023. PMID: 38248234 Free PMC article. Review.
-
The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer's Disease.Neuromolecular Med. 2024 Dec 29;27(1):2. doi: 10.1007/s12017-024-08815-z. Neuromolecular Med. 2024. PMID: 39751702 Review.
References
-
- Administration USFaD (2019) FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease. https://www.fda.gov/news-events/press-announcements/fda-approves-new-add...
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous